tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Garrity ER et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. 1999 J. Heart Lung Transplant. pmid:10328140
Ruzicka T et al. Tacrolimus: the drug for the turn of the millennium? 1999 Arch Dermatol pmid:10328199
Schmidt RH et al. Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. 1999 Nephrol. Dial. Transplant. pmid:10328486
Kohyama T et al. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. 1999 Mol. Cell Biol. Res. Commun. pmid:10329481
Tian J and Karin M Stimulation of Elk1 transcriptional activity by mitogen-activated protein kinases is negatively regulated by protein phosphatase 2B (calcineurin). 1999 J. Biol. Chem. pmid:10329725
Nakamura H et al. Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. 1999 J. Allergy Clin. Immunol. pmid:10329849
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Okamoto H The CD38-cyclic ADP-ribose signaling system in insulin secretion. 1999 Mol. Cell. Biochem. pmid:10331647
Iwamoto H et al. Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration. 1999 Graefes Arch. Clin. Exp. Ophthalmol. pmid:10333108
Henley SA et al. Lipids increase after solitary pancreas transplantation. 1999 Diabetes Care pmid:10333952
van den Berg JW et al. New immunosuppressive drugs and lung transplantation: last or least? 1999 Thorax pmid:10335012
Shirbacheh MV et al. Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. 1999 J. Pharmacol. Exp. Ther. pmid:10336506
Gold BG et al. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. 1999 J. Pharmacol. Exp. Ther. pmid:10336507
Steg RE et al. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. 1999 Bone Marrow Transplant. pmid:10338054
Ferrand-Drake M et al. Mitochondrial permeability transition induced DNA-fragmentation in the rat hippocampus following hypoglycemia. 1999 Neuroscience pmid:10338300
Conboy IM et al. Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10339586
Ma D and Carlow CK Molecular characterization of FKBP13 from filarial parasites. 1999 Mol. Biochem. Parasitol. pmid:10340490
Ruddy SB et al. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. 1999 Int J Pharm pmid:10341307
Uchio E et al. Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. 1999 Mar-Apr Clin. Exp. Rheumatol. pmid:10342043
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309